Article Versions Notes

De Giglio A, Mezquita L, Auclin E, Blanc-Durand F, Riudavets M, Caramella C, Martinez G, Benitez JC, Martín-Romano P, El-Amarti L, et al. Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). Cancers. 2020; 12(10):2827. https://doi.org/10.3390/cancers12102827

De Giglio, Andrea, Laura Mezquita, Edouard Auclin, Félix Blanc-Durand, Mariona Riudavets, Caroline Caramella, Gala Martinez, Jose Carlos Benitez, Patricia Martín-Romano, Lamiae El-Amarti, and et al. 2020. "Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)" Cancers 12, no. 10: 2827. https://doi.org/10.3390/cancers12102827

De Giglio, A., Mezquita, L., Auclin, E., Blanc-Durand, F., Riudavets, M., Caramella, C., Martinez, G., Benitez, J. C., Martín-Romano, P., El-Amarti, L., Hendriks, L., Ferrara, R., Naltet, C., Lavaud, P., Gazzah, A., Adam, J., Planchard, D., Chaput, N., & Besse, B. (2020). Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). Cancers, 12(10), 2827. https://doi.org/10.3390/cancers12102827